Median Technologies to present at Medidata NEXT Global 2017 to discuss how new technologies can optimize image management in clinical trials
Median Technologies, The Imaging Phenomics Company® (ALMDT:PA) is pleased to announce that James Golando, Chief of Operations at Median Technologies will present on “Optimizing...
Sandoz biosimilar Erelzi matches efficacy, safety profile of reference biologic in rheumatoid arthritis
Sandoz, a Novartis division and the global leader in biosimilars, announces results from the EQUIRA study. The phase III comparative safety and efficacy study...
Adaptive Biotechnologies Announces a Collaboration with Amgen to Advance Clinical Development of the clonoSEQ Assay in Multiple Myeloma
Adaptive Biotechnologies, a leader in combining next-generation sequencing (NGS) and sophisticated bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces...
Otsuka Announces Phase 3 Results for Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced detailed results from the Phase 3 REPRISE trial of tolvaptan, which is under investigation in the United States...
Phase 3 Study Of Subcutanous Daratumumab Initiated Using Halozyme’s ENHANZE Technology
Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Janssen Biotech, Inc. has initiated the first of three...
Daiichi Sankyo Announces ENLIVEN Phase 3 Study of Pexidartinib Met Primary Endpoint in Tenosynovial Giant Cell Tumor
Daiichi Sankyo Company, Limited announced that the pivotal phase 3 placebo-controlled ENLIVEN (NCT02371369) study of pexidartinib met its primary endpoint of tumor response as...
Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual...
Servier, Pfizer In and Cellectis announced that preliminary results from two phase 1 trials with UCART19, the allogeneic anti-CD19 CAR T-cell product being developed...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...